Akanksha Baharani, PhD
Medical Science Liaison at Roche Diagnostics
This presentation is on Alzheimer's Disease (AD) patient journey and Diagnostics. It addresses the changes associated with the disease and the cost burden on the medicare system. Emphasis will be given on the biomarkers associated with AD, namely Abeta and Tau, and their role in the manifestation of the disease. These biomarkers become abnormal 10-15 years before the appearance of clinical symptoms. They can be detected using our Elecsys CSF assays, which can be run on Roche fully automated cobas platform.